YHYue Hao

Yue Hao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yue Hao has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Xiyuan Ba

    Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Shenzhen Nanshan People's Hospital and the 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China

    6 shared publications
  • Donglin Xiong

    Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Shenzhen Nanshan People's Hospital and the 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China

    5 shared publications
  • Lizu Xiao

    Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Shenzhen Nanshan People's Hospital and the 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China

    5 shared publications
  • Xiya Chen

    School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China

    5 shared publications
  • Bo Liu

    Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

    4 shared publications
  • Changyu Jiang

    Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Shenzhen Nanshan People’s Hospital and the 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, People’s Republic of China

    4 shared publications

Latest Publications

  • Open Access

    HDAC7 acts as an astrocytic mediator of Aβ pathology that directly engages IKK to drive astrocyte neurotoxicity and neurodegeneration in Alzheimer’s disease

    by Jinwang Ye, Yunsong Deng, Bingge Zhang, Chengjia Li, Xing Guo, Ruizhu Yue, Huali Wan, Yue Hao, Shifeng Xiao

    Background: Astrocytes undergo reactive transformations in response to pathological stimuli and play a critical role in neuronal loss associated with Alzheimer’s disease (AD). However, the intrinsic mechanisms through which astrocytes detect amyloid-β (Aβ) pathology and develop neurotoxic properties remain inadequately understood. The dysregulation of class IIa Histone deacetylases (HDACs) has been implicated in astrocyte dysfunction under pathological conditions. This study aims to elucidate the role of HDAC7 as an astrocytic mediator of Aβ that drives the formation of neurotoxic reactive astrocytes, and to propose HDAC7 as a potential therapeutic target for mitigating neuronal loss and cognitive deficits in AD. Methods: We examined HDAC7 expression in APP/PS1 mice of varying ages using RT-qPCR, Western blotting, and immunostaining analysis. Astrocyte-specific HDAC7 overexpression and knockdown were achieved through adeno-associated virus (AAV) delivery (GfaABC1D promoter) in wild-type (WT) and APP/PS1 mice, followed by behavioral tests, immunostaining, RT-qPCR, and RNA-seq. Mechanistic studies were conducted using primary astrocytes derived from WT and Hdac7 flx/flx mice, employing co-immunoprecipitation, Western blotting, and neuron viability assays. Pharmacological inhibition of HDAC7 in APP/PS1 mice was performed via intraperitoneal injection of TMP195, and the effects on neurotoxic reactive astrocytes, neuronal and synaptic loss, and behavioral performance were measured. Results: HDAC7 was selectively upregulated in plaque-adjacent astrocytes in APP/PS1 mice. Overexpression of HDAC7 specifically in astrocytes was sufficient to induce a neurotoxic transcriptional profile, neuronal loss, and cognitive deficits in both WT and young APP/PS1 mice. Mechanistically, upon Aβ stimulation, the upregulated HDAC7 directly interacted with and deacetylated IKKα and IKKβ, resulting in the activation of IKK, translocation of NF-κB to the nucleus, and subsequent expression of neurotoxic genes. This neurotoxic conversion was dependent on IKK activity, as IKK inhibition nullified the effects in astrocytes overexpressing HDAC7. Conversely, astrocytic HDAC7 knockdown or treatment with TMP195 attenuated IKK-NF-κB signaling, reduced the presence of neurotoxic reactive astrocytes, and rescued neurodegeneration and cognitive deficits in APP/PS1 mice. Conclusions: HDAC7 acts as an intrinsic effector within astrocytes, responding to Aβ pathology and converting astrocytes into a neurotoxic state through direct interaction with IKK. Targeting HDAC7 presents a promising strategy for astrocyte-directed therapeutic interventions in Alzheimer’s disease.


  • Open Access

    (+)-Miliusol suppresses the Warburg effect and induces regulated cell death in triple-negative breast cancer through targeting EIF3D and remodeling cancer metabolism

    by Jin Zhang, Lin Jia, Xiya Chen, Yan Wu, Xiaohan Sun, Ling Zou, Xiaoling Cheng, Jingnan Huang, Hongchao Zhou, Lingyun Dai, et al.

  • Open Access

    Upregulated astrocytic HDAC7 induces depression-like disorders via deacetylating PINK1 and inhibiting mitophagy

    by Rui-Zhu Yue, Xing Guo, Cheng-Jia Li, Li-Juan Wu, Yu-Tong Liu, Juan Hu, Bing-Kang Yan, Hai-Tong Lin, Ying-Ling Tang, Wei-Ming Yan, et al.

    Major depressive disorder (MDD) is a prevalent mental disorder and the leading cause of disability worldwide. Emerging evidence indicates that dysregulation of astrocyte mitochondria metabolism contributes to the pathophysiology of depression. However, the molecular mechanisms underlying the stress-induced astrocytic dysfunction remain poorly understood. Here, we show that impaired mitophagy, which occurring downstream of increased Class IIa histone deacetylases 7 (HDAC7) expression, play a critical role in astrocytic mitochondria dysfunction in a Lipopolysaccharide (LPS)-induced depression-like mouse model. Astrocyte-specific overexpression of HDAC7 in the hippocampus disrupted PTEN-induced putative kinase 1 (PINK1)-Parkinson protein 2 (Parkin)-dependent mitophagy, leading to reduced mitochondrial ATP release, neuronal damage and depressive-like behaviors. Mechanistically, HDAC7 impairs mitophagy by deacetylating PINK1, thereby suppressing phosphorylation of Parkin at Ser65 and inhibiting recruitment of downstream proteins translocase of outer mitochondrial membrane (TOMM) 20 and 40. Notably, Astrocyte-specific knockout or pharmacological inhibition of HDAC7 attenuates LPS-induced astrocytic mitophagy disruption, oxidative stress and mitochondrial adenosine triphosphate (ATP) release, alongside recovery of neuronal activity and reverse of depressive-like behavioral disorders in mice. Taken together, our data shed light on the intricate interplay between astrocytes, neuronal damage, and mitophagy in the etiology of depression, offering promising therapeutic targets for the treatment of MDD and other astrocyte-associated disorders.


  • Open Access

    Solobacterium moorei promotes tumor progression via the Integrin α2/β1-PI3K-AKT-mTOR-C-myc signaling pathway in colorectal cancer

    by Yan Chen, Ying Qin, Tingting Fan, Cheng Qiu, Yijie Zhang, Mengmeng Dai, Yaoyao Zhou, Qinsheng Sun, Yuan Guo, Yue Hao, et al.

    More and more evidences show that the imbalance of intestinal flora homeostasis can contribute to the progression of colorectal cancer (CRC). Solobacterium moorei (S. moorei), an anaerobic Gram-positive bacillus, was found to be enriched in fecal samples from CRC patients. However, the signaling regulatory mechanism of S. moorei promoting CRC progression remain unknown. Three CRC mouse models (ApcMin/+ mice, AOM/DSS-treated mice and subcutaneous colorectal xenograft mice) and two cell lines (DLD-1 and HT-29) were used to investigate the biological functions and molecular mechanisms of S. moorei on tumor progression of CRC in vivo and in vitro. S. moorei abundance increased in fecal samples and tumor tissues, and was significantly positively correlated with tumor staging of CRC. S. moorei promoted tumor progression in various CRC mouse models and it selectively adhered to cancer cells in comparison to colonic mucosal epithelial cells, enhancing CRC cell proliferation and inhibiting cell apoptosis. Mechanistically, S. moorei cellwall protein Cna B-type domain-containing protein binds to integrin α2/β1 on CRC cells, leading to the activation of PI3K-AKT-mTOR-C-myc pathway via phospho-FAK, thereby promoted tumor cell growth and progression. Blockade of integrin α2/β1 abolished S. moorei-mediated oncogenic response in vitro and in vivo. In summary, this study demonstrated that S. moorei promoted tumor progression via the integrin α2/β1-PI3K-AKT-mTOR-C-myc signaling pathway, which is a novel specific pathogen-mediated mechanism that might be a new potential target for CRC prevention, diagnosis, and treatment.


  • Discovery of a novel CDK4/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma

    by Zizhou Niu, Zhichao Shi, Guoxiang Wu, Yanping Liu, Weibin Xie, Fakai Liu, Tingting Fan, Kaifei Shu, Qiuhua Huang, Mengmeng Dai, et al.


  • Open Access

    Activating autophagy improves paclitaxel-induced peripheral neuropathy in chemotherapy

    by Jin Zhang, Yelan Huang, Xiaohan Sun, Xiya Chen, Xi Zhao, Chenqiu Ran, Bo Liu, Yue Hao


  • Nicotinamide riboside activates SIRT3 to prevent paclitaxel-induced peripheral neuropathy

    by Xiaohan Sun, Weiting Huang, Dejin Yin, Xi Zhao, Xiaoling Cheng, Jin Zhang, Yue Hao


  • Open Access

    Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer

    by Wenjun Huang, Qingyun Zhu, Zhichao Shi, Yao Tu, Qinyuan Li, Wenwen Zheng, Zigao Yuan, Lulu Li, Xuyu Zu, Yue Hao, et al.

    The existing conventional treatments for breast cancer, including immune checkpoint blockade, exhibit limited effects in some cancers, particularly triple-negative breast cancer. Epigenetic alterations, specifically DNMT and HDAC alterations, are implicated in breast cancer pathogenesis. We demonstrated that DNMTs and HDACs are overexpressed and positively correlated in breast cancer. The combination of DNMT and HDAC inhibitors has shown synergistic antitumour effects, and our previously designed dual DNMT and HDAC inhibitor (termed DNMT/HDACi) 15a potently inhibits breast cancer cell proliferation, migration, and invasion and induces apoptosis in vitro and in vivo. Mechanistically, 15a induces a viral mimicry response by promoting the expression of endogenous retroviral elements in breast cancer cells, thus increasing the intracellular level of double-stranded RNA to activate the RIG-I–MAVS pathway. This in turn promotes the production of interferons and chemokines and augments the expression of interferon-stimulated genes and PD-L1. The combination of 15a and an anti-PD-L1 antibody had an additive effect in vivo. These findings indicate that this DNMT/HDACi has immunomodulatory functions and enhances the effectiveness of immune checkpoint blockade therapy.


  • Open Access

    Transcriptome analysis reveals dysregulation of inflammatory and neuronal function in dorsal root ganglion of paclitaxel-induced peripheral neuropathy rats

    by Wuping Sun, Shaomin Yang, Songbin Wu, Xiyuan Ba, Donglin Xiong, Lizu Xiao, Yue Hao

    Chemotherapy-induced peripheral neuropathy (CIPN) is the most common side-effect of anti-cancer therapy. To date, there are no clinically effective analgesics that could prevent and treat CIPN. However, the exact pathogenesis of CIPN is still unclear. In the present study, we use the paclitaxel-induced peripheral neuropathy (PIPN) model, aiming to better understand the transcriptomic level of the Dorsal root ganglia (DRG) neurons in rats with PIPN. mRNA from each DRG sample was reverse transcribed to cDNA and sequenced using next-generation high throughput sequencing technology. Quantitative RT-PCR verification was used to confirm the identified Differentially expressed genes (DEGs) in the DRG of PIPN rats. RNAseq results have identified 384 DEGs (adjusted P-value < 0.05; fold change ≥ 2) in the DRG of rats 14 days after paclitaxel injection in total, including 97 up-regulated genes, and 287 down-regulated genes. GO analysis revealed that these DEGs were majorly involved in neuropeptide activity, chemokine receptor activity, defense response, and inflammatory response. Kyoto Encyclopedia of Gene and Genomes analysis showed that neuroactive ligand-receptor interaction and cytokine-cytokine receptor interaction were involved in sensory neurons of rats with PIPN. Besides, comparison analysis identified that 11 DEGs in the PIPN model are shared with either inflammatory pain (Ces1d, Cfd, Retn, and Fam150b) or neuropathic pain (Atf3, Csrp3, Ecel1, Gal, Sprr1a, Tgm1, and Vip). Quantitative RT-PCR results also confirmed the validation of the RNAseq data. These results suggested that neuroactive ligand-receptor interaction and cytokine-cytokine receptor interaction are majorly involved in sensory neurons of rats with PIPN. Immune, inflammatory responses and neuron functional changes are the major pathogenesis of PIPN. Paclitaxel-induced peripheral neuropathy has shared characteristics with both inflammatory pain and neuropathic pain.